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1. Introduction 
The etiology of autoimmune diseases is multifactorial. The degree to which genetic and 
environmental factors influence susceptibility to autoimmune diseases is not fully 
understood. The antiphospholipid syndrome (APS) is characterized by vascular thrombosis, 
and/or pregnancy morbidity associated with anticardiolipin (aCL), anti-2-glycoprotein-I 
(anti-2-GPI) and lupus anticoagulant (LAC). [Levy et al., 2006]. 
1.1 Antiphospholipid syndrome 
Antiphospholipid syndrome (APS), first described between 1983 to 1986, is characterized by 
a wide variety of hemocytopenic and vaso-occlusive manifestations and is associated with 
antibodies directed against negatively charged phospholipids. Features of APS include 
hemolytic anemia, thrombocytopenia, venous and arterial occlusions, livedo reticularis, 
pulmonary manifestations, recurrent fetal loss, neurologic manifestations (stroke, transverse 
myelitis, Guillain-Barré syndrome); and a positive Coombs test, anticardiolipin antibodies, 
or lupus anticoagulant activity. The factor(s) causing production of the antiphospholipid 
antibodies in primary antiphospholipid syndrome (PAPS) remain unidentified. [Hughes, 
1993; Asherson et al., 1994; Yáñez et al., 1999]. 
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2. Mycoplasmas 
Mycoplasmas are eubacteria included within the Class Mollicutes, which comprises the 
smallest self-replicating bacteria, showing distinctive features such as: a) lack of a rigid cell 
wall envelope, b) sterol incorporation into their own plasma membrane, and c) reduced 
cellular (0.3 - 0.8 m diameter) and genome sizes (0.58-2.20 Mb). [Bove, 1993; Razin et al., 
1998]. Due to their reduced genome sizes, mycoplasmas exhibit restricted metabolic and 
physiological pathways for replication and survival [Razin et al., 1998]. Thus it is evident 
why these bacteria display strict dependence to their hosts for acquisition of aminoacids, 
nucleotides, lipids and sterols as biosynthetic precursors. [Baseman & Tully, 1997; Razin et 
al., 1998]. Currently, there are more than 200 species allocated into four orders, five families 
and eight genera within the Class Mollicutes [Brown et al., 2007]. All species of 
Mycoplasmataceae are obligate parasites and host specificity is quite strict for hosts 
including humans, rodents and birds. Mycoplasmal infections are most frequently 
associated with disease in the urogenital or respiratory tracts and, in most cases, 
mycoplasmas infect the host persistently. Like other parasites, many mycoplasma species 
display antigenic diversity, which has been noted in a variety of protein profiles or colony 
immunoblotting. [Sasaki, 2002].  
2.1 Immune response against mycoplasmas 
Host defense in mycoplasmal disease is dependent on both innate and humoral immunity. 
[Waites & Atkinson, 2009]. Molecular mimicry, survival within cells and phenotypic 
plasticity (antigenic variation) are the major mechanisms by which mycoplasmas evade the 
immune response [Chambaud et al, 1999; Razin et al., 1998; Rottem & Naot, 1998]. 
Association between immunodeficiency and mycoplasmal infections has been reported 
since the mid 1970s. Mycoplasmas can disseminate from localized infections and cause 
invasive diseases, especially in hypogammaglobulinemic subjects. [Cassell et al., 1994]. 
Antigenic variation is considered to be a strategy for persistence in the face of immune 
responses by the host. [Sasaki, 2002]. 
2.2 Diagnostic procedures 
Many mycoplasmal diseases are quite different than those for fast-growing bacteria. It is 
noteworthy that mycoplasmal etiology of respiratory diseases is considered only after 
failure of diagnosis of other common bacterial etiologies. In addition, there are few 
specialized or reference laboratories and skilled personnel [Cassell et al., 1994; Waites & 
Atkinson, 2009]. PCR testing for species-specific mycoplasmal infection is suitable for 
clinical diagnosis. A culture enhanced PCR approach has also been suggested to overcome 
the effect of inhibitors in the amplification process [Abele-Horne et al., 1998]. 
2.3 Treatment 
Due to absence of the cell wall envelope, mycoplasmas are insensitive to β-lactam 
antibiotics. However, antibiotics targeting protein synthesis or DNA modification molecules 
are highly effective against these bacteria. Macrolides, tetracyclines and fluoroquinolones 
eliminate mycoplasmas efficiently both in vivo and in vitro [Cassell et al., 1994; Waites & 
Atkinson, 2009].  
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3. Mycoplasma penetrans 
Mycoplasma penetrans infects humans in the urogenital and respiratory tracts. A typical 
feature of Mycoplasma penetrans is its penetration into human cells. Internalization of the 
organisms into the urothelium was detected in autopsy samples from an acquired 
immunodeficiency syndrome (AIDS) patient [Lo, et al., 1992]. Intracellular replication and 
persistence for at least 6 months has been observed in cultured cells. [Dallo, et al., 2000].  
Mycoplasma penetrans was first isolated from urine of homosexual men infected with (HIV), 
but not from healthy age-matched subjects. Subsequent studies suggested an association of 
this mycoplasma with Kaposi's sarcoma, but later findings did not confirm such association. 
[Baseman & Tully, 1997]. 
In humans, Mycoplasma penetrans is associated mainly with HIV‐1 infection, particularly in 
adults among the homosexual population in Europe and the USA, and among both 
homosexual and heterosexual males in South America. Anti‐ Mycoplasma penetrans 
antibodies are found even in asymptomatic HIV carriers and in patients in the process of 
developing AIDS [Lo, S.C. et al., 1992; Cordova, et al., 1999; Grau, et al. 1995; Lo, et al. 1991; 
Lo, et al. 1992, Lo, et al. 1993; Wang, et al. 1992; Wang, et al., 1993]. Both the rapid decline in 
CD4‐positive lymphocyte counts in Mycoplasma penetrans ‐seropositive HIV‐infected 
individuals and the mitogenic effects of this organism on lymphocytes imply a contribution 
of persistent Mycoplasma penetrans infection to the deterioration of the immune system in 
HIV infection. [Grau, et al. 1998; Sasaki, et al., 1995] 
On the other hand, Mycoplasma penetrans infection has also been suggested to be a primary 
cause of human disease in non‐HIV‐related urethritis and respiratory disease. [Cordova, et 
al, 1999; Yáñez et al. 1999] The Mycoplasma penetrans HF‐2 strain was isolated from a 
previously healthy HIV‐negative patient suffering from severe respiratory distress caused 
by Mycoplasma penetrans infection‐associated systemic disease. [Yáñez et al. 1999] 
The Mycoplasma penetrans HF‐2 strain possesses a 1.3 Mb genome, which is the largest 
among the Mycoplasmataceae species thus far analyzed. Sasaki et al., identified 1038 
putative coding DNA sequences (CDSs), among which 463 are Mycoplasma penetrans 
specific. The relatively large Mycoplasma penetrans genome compared with other 
mycoplasma genomes may be accounted for a probably rich core proteome. This data 
should be of great use for understanding the mechanism of Mycoplasma penetrans infection 
of humans and will also provide new insights into the regulation of virulence factors in 
Mycoplasma penetrans as well as other Mycoplasmataceae. [Sasaki, 2002].  
4. Objective 
The aim of this study was to determine the presence of antibodies against Mycoplasma 
penetrans in patients with antiphospholipid Syndrome. 
5. Material and methods 
5.1 Subjects 
Eighty-eight patients at the Rheumatology Service of the “Hospital Manuel Avila Camacho 
del Instituto Mexicano del Seguro Social” in Puebla City, Mexico were included in the study. 
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A rheumatologist examined the patients and all fulfilled the American College 
Rheumatology criteria. Eighteen patients were diagnosed with Primary Antiphospholipid 
Syndrome, 26 patients with Secondary Antiphospholipid Syndrome and 44 patients with 
Systemic Lupus Erythematosus (SLE).  
Forty four women without any autoimmune or infectious disease were included in the 
study as healthy women. Healthy women were not under antibiotic or drug treatment. The 
ethics committee of the Hospital approved this study and informed patient consent was 
obtained. 
5.2 Specimens 
Peripheral whole blood samples from patients and healthy women were collected in order 
to detect IgG, IgM and IgA antibodies against cardiolipin and 2 glycoprotein I using a 
ELISA Test. Immunoglobulin M and G against Mycoplasma penetrans were also investigated 
using ELISA and Western blot assays. Blood samples were collected in tubes without 
anticoagulant and stored at -200C until use.  
5.3 Detection of antibodies anticardiolipin using ELISA test 
Antibodies anticardiolipin and anti-2 glycoprotein I were tested in all patients and healthy 
persons. Diagnostic Automation Inc. ELISA test was used to detect IgG, IgA and IgM 
against cardiolipin and 2 glycoprotein I. 
5.4 Detection of antibodies against Mycoplasma penetrans by ELISA test 
Mycoplasma penetrans HF strain was cultured in E media, centrifuged at 12,000 rpm for 40 
min and suspended in PBS (0.015 M pH 7.4). This procedure was repeated 3 times until the 
suspension was adjusted to an OD600 = 1 using a carbonate buffer (0.1M pH 9.6). This 
suspension was considered the antigen. Two hundred microliters of antigen was added to 
each well of the plate. The plates were covered and incubated at 37oC for two hours. The 
plates were kept at 4oC for 4 days before use and antigen excess was removed. The plates 
were washed five times with PBS and then dried. Two hundred microliters of 2 % skim milk 
diluted in PBS-Tween 0.05% were added to each well of the plate. Plates were covered and 
kept at 4oC for one night, then, excess skim milk was removed. Two hundred microliters of 
patient´s sera diluted 1:200 in PBS-Tween 0.05% were added to each well plate and 
incubated at room temperature during night. Antihuman IgM or IgG alkaline-phosphatase 
conjugates diluted 1:1000 were added and incubated at room temperature for one hour. The 
conjugate was removed and the plates were washed five times with PBS/Tween (0.05 %). 
Two hundred microliters of alkaline phosphatase substrate was added to each well. These 
plates were incubated in the dark until a yellow color was visible and reaction was stopped 
adding 20 microliters of Na OH 1N in each well. Plates were read at 405 nm in a multiscan 
ELISA meter. Positive and negative controls were tested. 
5.5 Detection of antibodies against Mycoplasma penetrans using Western Blot tests 
Mycoplasma penetrans HF whole cell was used as an antigen. The bacteria was cultured in E 
media, centrifuged at 12,000 rpm for 40 min and suspended in PBS (0.015 M pH 7.4). This 
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procedure was repeated 3 times until the suspension was adjusted to an OD600 =1 using PBS 
and 750 microliters of this solution was mixed with 250 microliters of sample buffer (40 % 
glycerol, 240 mM Tris/HCl pH 6.8, 0.04% bromophenol blue, 5 % -mercaptoethanol and 
boiled during 10 minutes. A 14 % PAGE-SDS gel was used in order to separate proteins 
using 100 volts for 3 hours. The proteins were transferred to nitrocellulose (0.45 nm pore). 
Transfers were done using a semidry chamber at 15 volts for 15 minutes. Membranes were 
stained using amido black to verify proteins transference. The membranes were blocked 
using a 2% skim milk solution for 1 hour at room temperature. The IgM and IgG antibodies 
against Mycoplasma penetrans were detected using 2 nitrocellulose 5 mm wide strips in each 
patient’s serum diluted 1:50 in PBS. The strips were stirred constantly for 1 hour at room 
temperature and washed 5 times with PBS-Tween (0.05%). Each strip was in contact with 
the alkaline phosphatase conjugate (anti-human IgM or IgG) for 1 hour at room 
temperature. The strips were washed five times with PBS-Tween (0.05%) and presence of 
antibodies was detected with a mixture of 66 microliters of nitro blue tetrazolium (NTB), 33 
microliters of 5-bromo-4-cloro-3-indolilphosphate (BCIP), and 10 microliters of alkaline 
phosphatase buffer.  
5.6 Environmental data collection 
Patients and healthy people were questioned about environmental factors (living conditions, 
presence of pets at home, presence of rivers, garbage dumps or standing water, use of 
insecticide, presence of preeclampsia, infectious diseases and their medical history). 
6. Results 
Eighty eight patients were included in the study, 18 patients were diagnosed with Primary 
Antiphospholipid Syndrome (APS), 26 patients with Secondary Antiphospholipid 
Syndrome and 44 patients with Systemic Lupus Erythematosus. All patients were females 
whose age ranged from 13 to 64 years old. 
6.1 Anticardiolipin antibodies 
Five patients with Primary APS tested positive for anticardiolipin and anti-2 glycoprotein I 
(5/18), five patients with Secondary APS tested positive (5/26) in remained 13 Primary APS 
and 21 Secondary APS patients, lupus anticoagulant were present. Two patients with SLE 
(2/44), none of the healthy persons were positive (0/44) for anticardiolipin and anti-2 
glycoprotein I antibodies. X2 was calculated and it showed an association between 
anticardiolipin antibodies and primary APS (p= 0.006) 
6.2 Detection of antibodies against Mycoplasma penetrans by ELISA 
 
Antibodies against 
Mycoplasma penetrans 
Primary APS Secondary APS SLE Healthy 
Persons 
Ig G 8/18 (44 %) 20/26 (77%) 20/44 (45%) 2/44 (4%) 
Ig M 14/18 (78%) 22/26 (85%) 33/44 (75%) 2/44 (4%) 
X2 was calculated, there was an association between presence of both Ig G and IgM 
antibodies with Secondary APS 
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6.3 Detection of antibodies against Mycoplasma penetrans using Western Blot 
 
Antibodies against 
Mycoplasma penetrans 
Primary APS Secondary APS SLE Healthy 
Persons 
Ig G 13/18 (72%) 11/19 (55%) 13/24 (54%) 2/44 (4%) 
Ig M 13/18 (72%) 13/19 (68%) 16/24 (67%) 2/44 (4%) 
X2 was calculated p>0.05. There was no association between the development of antibodies 
and disease.  
We performed first the detection of antibodies using ELISA test and then using Western Blot 
test. Unfortunately we did not have enough serum from 7 patients with Secondary APS and 
20 patients with SLE and we could not contact them to get more sample. 
6.4 Presence of antibodies in patients and controls 
 
Antibody Primary APS Secondary 
APS
SLE Healthy 
persons 
Anticardiolipin and 
Anti-2 glycoprotein I
6/18 (33%) 5/26 (19%) 2/44 (4%) 0/44 (0%) 
IgG vs Mycoplasma 
penetrans (ELISA) 
8/18 (44%) 20/26 (77%) 20/44 (45%) 2/44 (4%) 
IgM vs Mycoplasma 
penetrans (ELISA) 
14/18 (78%) 22/26 (85%) 33/44 (75%) 2/44 (4%) 
IgG vs. Mycoplasma 
penetrans (Western blot)
3/18 (72%) 11/19 (55%) 13/24 (54%) 2/44 (4%) 
IgM vs. Mycoplasma 
penetrans (Western blot) 
3/18 (72%) 13/19 (68%) 16/24 (67%) 2/44 (4%) 
X2 was calculated p<0.0007. There was an association between presence of antibodies only in 
patients with APS and SLE. 
6.5 Presence of environmental factors 
 
Environmental 
Factors 
Primary 
APS 
Secondary 
APS 
SLE Healthy 
Persons 
Lack of running water, electricity 
and sewage system 
1/18  
(5%) 
5/26  
(19%) 
1/44 (2%) 3/44  
(7%) 
More than 3 people sleeping in the 
same room 
1/18  
(5%) 
3/26  
(11%) 
11/44 
(25%) 
8/44 
(18%) 
Presence of pets (dogs, cats and 
birds) at home 
11/18 
(61%) 
13/26  
(50%) 
30/44 
(68%) 
30/44 
(68%) 
Presence of rivers, garbage dumps or 
standing water near their houses 
8/18 
(44%) 
12/26  
(46%) 
22/44 
(50%) 
15/44 
(34%) 
Frequent use of insecticide 6/18 
(33%) 
11/26  
(42%) 
13/44 
(30%) 
16/44 
(36%) 
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Environmental 
Factors 
Primary 
APS 
Secondary 
APS 
SLE Healthy 
Persons 
Preeclampsia 1/18  
(5%) 
4/26  
(15%) 
6/44 
(14%) 
6/44 
(14%) 
Common presence of infectious 
diseases 
8/18 
(44%) 
8/26  
(31%) 
23/44 
(52%) 
1/44  
(2%) 
Seasonal aggravation of symptoms 13/18 
(72%) 
12/26  
(46%) 
32/44 
(72%) 
0/44  
(0%) 
Family medical history of rheumatic 
diseases 
3/18 
(17%) 
10/26  
(38%) 
18/44 
(41%) 
3/44  
(7%) 
X2 was calculated p<0.0001. There was an association between presence of some 
environmental factors and disease. 
7. Discussion 
The etiology and pathogenesis of most autoimmune diseases, including the APS, remain 
unclear, with the involvement of infectious, autoimmune, and auto inflammatory pathways 
possibly being implicated. Infection may initiate a disease, although it is the combination of 
genetic regulation in the host, the interplay between virus or bacteria persistence, and 
autoimmunity that produces the later phases of disease, the antigenic determinants 
responsible for inducing autoimmune disease, and the pathogenic effector mechanisms. 
[Garcia-Carrasco et al., 2009]. 
Cervera et al., analyzed the clinical characteristics of 100 patients with antiphospholipid 
syndrome (APS) associated with infections. The main clinical manifestations of APS 
included: pulmonary involvement (39%), skin involvement (36%), and renal involvement 
(35%); nine with renal thrombotic microangiopathy. The main associated infections and 
agents included skin infection (18%), HIV (17%), pneumonia (14%), hepatitis C (13%), and 
urinary tract infection (10%). They concluded that various different infections can be 
associated with thrombotic events in patients with APS, including the potentially lethal 
subset termed catastrophic APS. [Cervera et al., 2004]. 
Infectious agents can play a dual role in the etiopathogeny of APS, acting as the initial 
trigger of the production of antibodies cross-reacting with 2 glycoprotein I (2GPI) and 
infectious peptides, and also inducing an inflammatory response. This is the so-called “two-
hit theory” in which pathogenic anti-2GPI antibodies act as the first hit and inflammatory 
responses as the second. [Amital et al. 2008; García-Carrasco et al. 2009].
Antiphospholipid antibodies (aPL) may be demonstrated during the course of many 
infections in addition to occurring in conditions such as Systemic Lupus Erythematosus 
(SLE), APS, and a wide variety of other rheumatic diseases. Syphilis was the first infection to 
be linked with aPL: one of the components of the VDRL reagent (cardiolipin) being 
responsible for the original finding that antibodies thought initially to be directed against 
cardiolipin were, in fact, pivotal in the pathogenesis and for the diagnosis of the APS. 
[Asherson, R.A., & Shoenfield, Y., 2003].
Interestingly, it has been reported that a substantial number of patients with Mycoplasma 
pneumoniae–induced respiratory disease have anticardiolipin antibodies. Furthermore, many 
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clinical criteria for APS have also been well documented in patients with M. pneumoniae 
infection, including Guillain-Barré–like illness and other central nervous system 
manifestations, hemolytic anemia, positive Coombs test, thrombocytopenia, and arthritis. 
[Asherson et al., 1994; Snowden et al., 1990; Yáñez et al., 1999]. 
Snowden et al. (1990) found antiphospholipid antibodies in more than 50% of patients with 
M. pneumoniae pneumonia, especially those with severe infections requiring hospitalization. 
Catteau et al., described two cases of Stevens-Johnson syndrome associated with M. 
pneumoniae infection and the presence of antiphospholipid antibodies. [Snowden et al., 1990; 
Catteau et al., 1995].
In a previous work, Mycoplasma penetrans was isolated from the blood and throat of a 
previously healthy non-HIV-infected 17-year-old woman sexually inactive who had an 
acute onset of arthritis, fever, and hemolytic anemia. Upon hospital admission, she 
developed respiratory distress, severe hemolytic anemia, leukocytosis, and 
thrombocytopenia. Blood and bone marrow smears did not show a neoplasic process. She 
was treated with methylprednisolone and trimethoprim/sulfamethoxazole on day 2, but her 
condition deteriorated. On day 3, the antibiotic treatment was changed to ceftazidime. On 
day 4 severe respiratory distress and hypoxemia developed, and the patient was admitted to 
the intensive care unit. Venereal Disease Research Laboratory (VDRL) tests were negative as 
were tests for Systemic Lupus Erythematosus. The patient was shown to have anti-dsDNA 
antibodies but positive anticardiolipin antibodies by ELISA test. Respiratory secretions were 
culture-negative and were shown to be negative by immunofluorescence for respiratory 
syncytial virus, adenovirus, influenza A, influenza B, parainfluenza 1,2,3, and Chlamydia. 
Serologic analysis indicated that the patient had no antibodies against HIV, hepatitis B or C 
virus. No acid-fast bacilli or other bacteria were observed on blood and tracheal aspirate 
smears. In addition, thoracic radiography showed only bilateral diffuse pulmonary 
infiltrates. On day 2 of hospital admission, blood and throat samples were cultured for 
aerobic flora and mycoplasma. Mycoplasma penetrans was isolated in a pure culture from the 
patient's blood (isolate HF-1) and throat (isolate HF-3). Later Mycoplasma penetrans was 
isolated from tracheal aspirate in pure culture (isolate HF-2). Treatment was initiated on day 
6 with clindamycin and vancomycin. The patient also received transfusion of two units of 
washed red blood cells. After 3 days of treatment, the patient improved clinically and was 
released from the intensive care unit on day 9; thoracic radiographs were clear. [Yáñez et al., 
1999].
Mycoplasma penetrans infection was detected in the APS patient's specimens prior to culture 
and was confirmed by specific polymerase chain reaction (PCR). Similar results were 
obtained by another pair of PCR primers also within the 16S rRNA gene and designed for 
the specific detection of Mycoplasma penetrans. Samples from both original specimens and 
broth cultures were tested by PCR for other human mycoplasmas, but none were detected. 
This finding was the basis of our present study, where the main purpose was to determine if 
the presence of Mycoplasma penetrans is a casual event or the bacteria may play a role in the 
pathogenesis of APS and SLE. [Yáñez et al., 1999].
Since autoimmune diseases may be influenced by environmental factors, we questioned 
patients about the presence of these factors. Some aspects about the epidemiology and 
pathogenesis of Mycoplasma penetrans infections remain unknown, so some questions try to 
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search for the primary habitat of the bacteria and others about the contact of the patients 
with some environmental factors that may influence the development of APS and SLE. 
[Yáñez et al., 1999].
Mycoplasmas are the smallest free living microorganisms and also defined as fastidious 
bacteria because of their nutritional requirements that is why the detection used 
immunological techniques to determine if the presence of antibodies anti- Mycoplasma 
penetrans are common in patients with APS and SLE but they are absent or in a low proportion 
of healthy people. IgG and IgM antibodies were detected suggesting a recent infection in the 
patient and/or a permanent contact of the bacteria with the host. Most patients were under 
corticosteroid or immunosuppressive therapy. These treatments may favor the persistence of 
Mycoplasma penetrans in patients with APS and SLE. [Yáñez et al., 1999].
The presence of Mycoplasma penetrans may not be casual and it could favor the 
development of APS or SLE. Mycoplasma penetrans is able to produce Phospholipase A2. 
This enzyme degrades the phospholipids of the host membrane and helps Mycoplasma 
penetrans in the penetration to the host cell [Salman, et al., 1998; Rottem, S., 2003]. It is well 
known that mycoplasmas induce autoimmune diseases in appropriate hosts. [Baseman & 
Tully, 1997; Waites & Atkinson, 2009]. Previous studies suggest that mycoplasmas may 
induce antiphospholipid antibodies [Snowden, et al., 1990; Yáñez et al., 1999]. Although 
there was an association between common presence of infectious diseases and seasonal 
aggravation of symptoms and/or APS and SLE, more studies need to be done. It was not 
possible to establish an association between the presence of an environmental factor and 
APS and SLE.
8. Conclusion 
Mycoplasma penetrans was first reported in 1993 as an emerging infectious agent. Yáñez et al., 
1999 reported the first of Mycoplasma penetrans isolation in a non-HIV-infected patient with 
APS. The mycoplasma strain isolated from the APS patient exhibited typical morphologic 
features of Mycoplasma penetrans, which are unique among mycoplasmas isolated from 
humans. The lack of Mycoplasma penetrans strong humoral response in the APS patient was a 
factor in favor of dissemination of the mycoplasma, hence its isolation from the blood. A 
possible association between Mycoplasma penetrans and APS should be considered.  
Antibodies against Mycoplasma penetrans in a high proportion of APS or SLE patients 
suggest that the presence of the bacteria is not casual and mycoplasmas may play a role in 
the development of these diseases. 
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